CN1111282C - Phlegm-treating agent for examining cancer cells - Google Patents
Phlegm-treating agent for examining cancer cells Download PDFInfo
- Publication number
- CN1111282C CN1111282C CN 00110366 CN00110366A CN1111282C CN 1111282 C CN1111282 C CN 1111282C CN 00110366 CN00110366 CN 00110366 CN 00110366 A CN00110366 A CN 00110366A CN 1111282 C CN1111282 C CN 1111282C
- Authority
- CN
- China
- Prior art keywords
- phlegm
- treating agent
- present
- preventing
- milliliters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a phlegm treating agent for examining lung cancer cells. The present invention comprises cetyl ammonium bromide, propylene glycol and ethanol, and has the functions of dissolving phlegm mucus, preventing the corrosion and fixing cancer exfoliative cells. When carbowax and isotonic phosphate buffer solutions are added into the phlegm treating agent of the present invention, the phlegm treating agent of the present invention has the functions of cell humidifying during flaking, cytomorphosis preventing and cytoclasis preventing. A smear and microscopy method by using the phlegm treating agent for dissolving phlegm samples has the advantages of simplicity, easy implementation, high positive detection rate, high accuracy and high reliably and is suitable for the general survey on lung cancer high risk groups and the clinical cytology diagnose.
Description
Affiliated field
The present invention relates to a kind for the treatment of agent that is used for the sputum sample of examining cancer cells.Be applicable to lung cancer people at highest risk generaI investigation and clinical cytology diagnosis.
Background technology
The clinical inspection diagnosis and the main method of cytology somatotype to lung cancer is pathological examination to lung cancer, the sample that is used for pathologic finding generally is to get by bronchoscopic forceps, swollen thing puncture of lung and sputum obtain, because of pincers are got and lung puncture is got sample the patient is caused certain painful and damage, so sputum is that the method for sample is more simple and easy to do, is widely used in clinical diagnosis.
Summary of the invention
Lung carcinoma cell mainly adopts the sputum specimen method of direct smear in the clinical examination sputum at present, because thick sputum, mucus is covered the cell composition, being not easy to smear and microscopy observes, and the cast-off cells in the sputum are dispersed in the mucus, make the cell density in the visual field little, the yielding or destruction of cell, it is low to detect positive rate.
The purpose of this invention is to provide mucus in a kind of dissolving phlegm, be easy to make qualified cell smear, can make that the cell composition fully dissociates out in the phlegm, the cell density in the visual field becomes hundred times of ground to increase, the rate height is examined in inspection, and the phlegm-treating agent that is used for examining cancer cells anticorrosion, bacteriostasis is arranged.
Phlegm-treating agent of the present invention contains dissolving mucus, fixing cancer cell, and the component of antiseptic and inhibiting bacteria function is characterized in that it is made up of following part by weight component:
Cetyl ammonium bromide 0.1-0.8%
Propylene glycol 1-10%
Ethanol 20-40%
And the distilled water of surplus.
For the ease of smear, keep the humidity of cancer cell, add the part by weight component of carbowax 0.5-1.0%.
For preventing sputum cancer cell deformation and failure, add isotonic phosphate buffer liquid in addition, its part by weight component is as follows:
Sodium chloride 0.1-0.30%
Sodium dihydrogen phosphate 0.65-0.85%
Dipotassium hydrogen phosphate 0.18-0.20%
Dibastic sodium phosphate 0.03-0.05%
Preparation method: cetyl ammonium bromide, carbowax be dissolved in 10% the distilled water, again isotonic phosphate buffer liquid component be dissolved in 50% the distilled water,, shake up promptly with adding the distilled water of propylene glycol, ethanol and surplus behind two kinds of solution mixings.
Using method: it is in 100 milliliters the collection sputum test tube that 40 milliliters of the phlegm-treating agents prepared are sub-packed in volume, issues the person under inspection, leaves and takes phlegm morning on the three continuously, coughs in the 1-2 mouth phlegm inlet tube censorship after three days every day.The phlegm pipe of censorship is centrifugal 10 minutes with 1000 rev/mins, discard most of supernatant, leave and take a small amount of supernatant, with suction pipe sediment and liquid are stirred evenly, draw one on microslide, be drawn into cell smear with another microslide to pressing pusher, dye microscopy behind the sheet with " hematoxylin-eosin " decoration method.
The phlegm-treating agent that the present invention is used for the inspection of lung carcinoma cell dissolves sample after centrifugal, precipitation sampling microscopy, prevented the interference of thick liquid to film-making, make the cell composition fully dissociate out, the cell density in the visual field becomes hundred times of ground to increase, and has improved the detection positive rate.Treating agent of the present invention has anticorrosion, antibacterial effect, helps film-making operator's health.
In clinical examination 1346 examples, make a definite diagnosis lung cancer person's 228 examples, suspicious lung cancer person's 124 examples at the phlegm-treating agent of the Anshan iron and steel plant SHUGUANG HOSPITAL internal application embodiment of the invention 3 preparation.Lung cancer person's 228 examples that detect through sputum, be diagnosed as patient's 326 examples of lung cancer through radiotherapy, chemotherapy surgery Pathology, the positive rate that proves sputum examination is 69.9%, and the unprocessed film-making inspection of sputum sample, detect 74 examples in the formerly certified 210 routine patients with lung cancer, positive rate is 35.2%.
Embodiment
Embodiment 1
Cetyl ammonium bromide 4 grams, 315 milliliters of 95% ethanol, 20 milliliters of propylene glycol, 665 milliliters of distilled waters.
The preparation method: the cetyl ammonium bromide is dissolved in 100 milliliters of distilled waters, and mixing shakes up promptly behind 565 milliliters of distilled waters of adding and ethanol, the propylene glycol.
Embodiment 2
Cetyl ammonium bromide 4 grams, carbowax 1 gram, 315 milliliters of 95% ethanol, 20 milliliters of propylene glycol, 665 milliliters of distilled waters.
Preparation method: cetyl ammonium bromide and carbowax are dissolved in 100 milliliters of distilled waters, shake up promptly behind 565 milliliters of distilled water of adding, ethanol, the propylene glycol.
Embodiment 3
Cetyl ammonium bromide 4 grams, carbowax 1 gram, 315 milliliters of 95% ethanol, 20 milliliters of propylene glycol, 665 milliliters of distilled waters, sodium chloride 2 grams, sodium dihydrogen phosphate 7.568 grams, dipotassium hydrogen phosphate 1.86 grams, sodium bicarbonate 0.4 gram.
Preparation method: cetyl ammonium bromide 4 grams, carbowax 1 gram are dissolved in 100 milliliters of distilled waters, again with sodium chloride 2 grams, sodium dihydrogen phosphate 7.568 grams, dipotassium hydrogen phosphate 1.86 grams, sodium bicarbonate 0.4 gram is dissolved in 500 milliliters of distilled waters, with above-mentioned two liquid mixings, add 315 milliliters of 95% ethanol, shake up promptly behind 65 milliliters of 20 milliliters of propylene glycol and the distilled waters.
Claims (3)
1. phlegm-treating agent that is used for examining cancer cells is characterized in that it is made up of following part by weight component:
Cetyl ammonium bromide 0.3-0.6%
Propylene glycol 1-10%
Ethanol 20-40%
And the distilled water of surplus.
2. phlegm-treating agent according to claim 1 is characterized in that wherein adding the part by weight component of carbowax 0.05-1.0%.
3. phlegm-treating agent according to claim 1 and 2 is characterized in that adding isotonic phosphate buffer liquid, and its part by weight component is as follows:
Sodium chloride 0.1-0.30%
Sodium dihydrogen phosphate 0.65-0.85%
Dipotassium hydrogen phosphate 0.18-0.20%
Dibastic sodium phosphate 0.03-0.05%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00110366 CN1111282C (en) | 2000-04-26 | 2000-04-26 | Phlegm-treating agent for examining cancer cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00110366 CN1111282C (en) | 2000-04-26 | 2000-04-26 | Phlegm-treating agent for examining cancer cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1320819A CN1320819A (en) | 2001-11-07 |
| CN1111282C true CN1111282C (en) | 2003-06-11 |
Family
ID=4580360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00110366 Expired - Fee Related CN1111282C (en) | 2000-04-26 | 2000-04-26 | Phlegm-treating agent for examining cancer cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1111282C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101988875A (en) * | 2010-09-03 | 2011-03-23 | 江苏省原子医学研究所 | Sputum liquid-based treating fluid |
| CN103471892A (en) * | 2013-09-22 | 2013-12-25 | 厦门大学附属第一医院 | Method for preparing pulled type cervical smear |
| CN103884549B (en) * | 2014-02-11 | 2016-03-02 | 中国人民解放军北京军区总医院 | A kind of phlegm cell treating fluid and application thereof |
| CN111238893B (en) * | 2020-01-19 | 2023-05-23 | 湖北泰康医疗设备有限公司 | Extraction method of humoral cells for detecting lung cancer |
-
2000
- 2000-04-26 CN CN 00110366 patent/CN1111282C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1320819A (en) | 2001-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aisner et al. | Torulopsis glabrata infections in patients with cancer: increasing incidence and relationship to colonization | |
| Steensberg et al. | Epidemiology of urinary tract diseases in general practice | |
| CN1111282C (en) | Phlegm-treating agent for examining cancer cells | |
| Maartens et al. | The clinical presentation and diagnosis of invasive fungal infections | |
| Roggli et al. | Comparison of sputum and lung asbestos body counts in former asbestos workers | |
| US4351823A (en) | Diagnosis of tumors or bacterial infections having β-glucuronidase activity | |
| Liu et al. | Bilateral parotid and submandibular gland enlargement: rare features of Wegener’s granulomatosis | |
| Imwidthaya | Mycotic keratitis in Thailand | |
| CN112741080B (en) | Liquid-based cell preservation treatment liquid and preparation method and application thereof | |
| CN102512463B (en) | Extraction method of nettle extract | |
| CN103163162A (en) | Method for identifying nanogold in tetrahymena thermophila in situ by transmission electron microscope and energy spectrum | |
| Kay et al. | Mild abnormalities in liver histology associated with chronic hepatitis: distinction from normal liver histology. | |
| CN1184963C (en) | Bromhexine hydrochloride injection and its preparation method | |
| Randhawa et al. | Survey of Cryptococcus neoformans in the respiratory tract of patients with bronchopulmonary disorders and in the air | |
| CN107596343A (en) | A kind of purposes of recombination human source cell line albumen in the medicine for preparing prevention or treatment pulmonary fibrosis disease | |
| CN114403130B (en) | Liquid-based cell preservation solution and preparation method and application thereof | |
| Sarkar et al. | The diagnostic value of routine culture of bronchial washings in turberculosis | |
| Özen et al. | DMSA renal scanning versus urography for detecting renal scars in vesicoureteral reflux | |
| Judson et al. | Recent micturition does not affect the detection of urethral gonorrhoea. | |
| CN113244268A (en) | Bacteriostatic gel containing sulfated polysaccharide-nano silver complex and application thereof | |
| Ediz et al. | Follicular cystitis: a review of the literature with several cases | |
| Sohn et al. | The Effect of Chemotherapy on Tuberculous Pleurisy: A Serial Study of 191 Needle Biopsy Specimens in 41 Patients | |
| Rostami et al. | A rare case of empyema necessitatis sustained by Nocardia farcinica in a kidney transplant recipient | |
| Pratiwi | Overview of Blood Enterprises (ESR) Using the Westergren Method in Tuberculosis Suspects in the Region of the Kabila Puskesmas, 2020 | |
| Furey et al. | The practical importance of synovial-fluid analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |